| |
| |
 |
Midway though the cruellest month, First Opinion authors criticized the word play used to void the travel mask mandate, asked if the shadow of Aduhelm will cloud the FDA's future decisions on new drugs, and more. You can read all of the week's essays here. For podcast fans, the latest episode of the "First Opinion Podcast," on the sorry state of care in many U.S. nursing homes, is live. |
| |
| By Jeffrey E. Harris PATRICK T. FALLON/AFP via Getty Images Wordplay should not determine if a federal agency has the authority to take measures to block the transmission of a lethal virus. Read More |
| By Haider J. Warraich John Moore/Getty Images A severe back injury gave one doctor insights into the plight of the 50 million Americans who live with chronic pain. Read More |
| By Bernard Zipprich Adobe Amylyx applied for approval of AMX0035, its new drug to treat ALS. Then the FDA's disastrous decision on Aduhelm happened. Read More |
| Sponsor content by Johnson & Johnson MedTech Putting medtech to work to solve the complex medical challenges How will science address the pervasive medical conditions that impact so many lives? By bringing the right voices to the table. Treating complex diseases like lung cancer – the most commonly diagnosed cancer worldwide – requires an integrated approach that blends the best of medical technology, software and biopharmaceuticals. With the brightest minds of these disciplines working together, we can pave the way to a healthier future for everyone, everywhere. Learn how here. |
| By Patrick Skerrett This week's "First Opinion Podcast" explores the "ineffective" and "inequitable" ways that many nursing homes care for their residents. Read More |
| By Benjamin F. Miller Adobe Lack of support and funding jeopardizes the rollout of 988, the new nationwide mental health and suicide prevention crisis hotline. Read More |
| By Dawn Sinclair Shapiro Adobe Vaccine and drug developers need to evaluate sex differences as an integral part of their preclinical and clinical work. Read More |
| By Walter G. Johnson and Diana M. Bowman Odra Noel/Wellcome The budget bill rider that funds the FDA mistakenly shuts down research on mitochondrial replacement, which could benefit some families. Read More |
| By Scott Swain and Kristin M. Zimmerman Savill and Bruce Feinberg Adobe A value-based care model cannot be generated from traditional trials alone. Something new — value-based research — is needed. Read More |
| By Alyssa Jaffee Adobe It's impossible to say how health care will be affected by the "bubble," if there is one. So companies should keep their eyes on their goals. Read More |
| By Richard N. Formica PIERRE-PHILIPPE MARCOU/AFP/Getty Images Changes made in how donated kidneys and other organs are allocated has helped improve access to transplants for all people. Read More |
No comments